Benoit Beuselinck

Leuven, VLG, Belgium

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 139 publications

Local control of RCC pancreatic metastases is obtained by angiogenesis inhibitors.

Local control of RCC pancreatic metastases is obtained by angiogenesis inhibitors.

Journal: Acta clinica Belgica

Published: September 03, 2026

MRONJ risk associated with combined antiresorptive and vascular endothelial growth factor receptor tyrosine kinase inhibitors.

MRONJ risk associated with combined antiresorptive and vascular endothelial growth factor receptor tyrosine kinase inhibitors.

Journal: Bone reports

Published: May 29, 2026

Clinical and Molecular Validation of the Very Favorable IMDC Risk Group in Metastatic Renal Cell Carcinoma.

Clinical and Molecular Validation of the Very Favorable IMDC Risk Group in Metastatic Renal Cell Carcinoma.

Journal: JAMA network open

Published: April 15, 2026

International metastatic renal cell carcinoma database consortium classification and regression tree analysis to characterize objective response rates to first line in metastatic renal cell carcinoma.

International metastatic renal cell carcinoma database consortium classification and regression tree analysis to characterize objective response rates to first line in metastatic renal cell carcinoma.

Journal: Frontiers in oncology

Published: March 10, 2026

Incidence and impact of pseudoprogression and mixed responses in metastatic renal cell carcinoma patients treated with ipilimumab/nivolumab: a retrospective analysis.

Incidence and impact of pseudoprogression and mixed responses in metastatic renal cell carcinoma patients treated with ipilimumab/nivolumab: a retrospective analysis.

Journal: Acta oncologica (Stockholm, Sweden)

Published: January 26, 2026

Lamina dura thickening in patients on antiresorptive therapy as a radiographic risk indicator of MRONJ: a retrospective longitudinal cohort study.

Lamina dura thickening in patients on antiresorptive therapy as a radiographic risk indicator of MRONJ: a retrospective longitudinal cohort study.

Journal: Dento maxillo facial radiology

Published: January 05, 2026

Prognostic and Predictive Value of the Clearseq1-4 Tumor Microenvironment Classification in Localized and Metastatic Clear-Cell Renal Cell Carcinoma.

Prognostic and Predictive Value of the Clearseq1-4 Tumor Microenvironment Classification in Localized and Metastatic Clear-Cell Renal Cell Carcinoma.

Journal: Cancer research communications

Published: September 10, 2025

Immuno-molecular features and therapeutic implications of brain metastases in clear cell renal cell carcinoma patients.

Immuno-molecular features and therapeutic implications of brain metastases in clear cell renal cell carcinoma patients.

Journal: Genes and immunity

Published: September 02, 2025

Outcomes of Patients with Metastatic Non-clear Cell Renal Cell Carcinoma Receiving Contemporary or Traditional First-line Therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.

Outcomes of Patients with Metastatic Non-clear Cell Renal Cell Carcinoma Receiving Contemporary or Traditional First-line Therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.

Journal: European urology oncology

Published: August 23, 2025

Understanding the genetic basis of medication-related osteonecrosis of the jaw: A systematic review.

Understanding the genetic basis of medication-related osteonecrosis of the jaw: A systematic review.

Journal: Bone

Published: July 30, 2025

Stereotactic Body Radiotherapy for Extracranial Oligometastatic Renal Cell Carcinoma: State of the Art and Future Perspectives.

Stereotactic Body Radiotherapy for Extracranial Oligometastatic Renal Cell Carcinoma: State of the Art and Future Perspectives.

Journal: Technology in cancer research & treatment

Published: July 17, 2025

CABOSEQ 3-Comparison of Cabozantinib versus Sunitinib Following First-Line Nivolumab- Ipilimumab for Metastatic Renal Cell Carcinoma: A Target Trial Emulation Using Real-World Data from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).

CABOSEQ 3-Comparison of Cabozantinib versus Sunitinib Following First-Line Nivolumab- Ipilimumab for Metastatic Renal Cell Carcinoma: A Target Trial Emulation Using Real-World Data from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).

Journal: Clinical genitourinary cancer

Published: June 12, 2025

Showing 1-12 of 139

Last Updated: 09/26/2026